DEK and juvenile myelomonocytic leukemia: HDAC1 has been shown to modulate KLF4 expression, suggesting HDAC1 and KLF4 as potential new molecular markers and targets for clinical diagnosis, prognosis, and treatment of myeloid leukemia [64]; TBL1XR1 is a fusion partner of several genes in leukemias such as TBL1XR1-RARA fusion in APL, TBL1XR1-ROS1 fusions in JMML, TBL1XR1-PDGFRB, a novel fusion in AML patients with DEK-NUP214 fusion [65].